v3.25.4
Earnings Per Share - Schedule of Computation of Basic and Diluted Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Numerator:      
Net income (loss) from continuing operations $ 27,274 $ (47,049) $ (121,196)
Net (income) loss attributable to noncontrolling interests—continuing operations (4,542) 10,924 24,458
Net income (loss) attributable to Bioventus Inc. Class A common stockholders—continuing operations 22,732 (36,125) (96,738)
Loss from discontinued operations, net of tax 0 0 (74,429)
Loss attributable to noncontrolling interest - discontinued operations 0 0 14,937
Net loss attributable to Bioventus Inc. Class A common stockholders—discontinued operations $ 0 $ 0 $ (59,492)
Denominator:      
Weighted-average shares of Class A common stock outstanding - basic (in shares) 66,622,631 64,547,474 62,647,554
Dilutive effect of stock options (in shares) 953,822 0 0
Dilutive effect of restricted stock units (in shares) 1,338,442 0 0
Weighted-average shares of Class A common stock outstanding - diluted (in shares) 68,914,895 64,547,474 62,647,554
Net loss per share of Class A common stock from continuing operations, basic (in dollars per share) $ 0.34 $ (0.56) $ (1.54)
Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) 0 0 (0.95)
Basic (in dollars per share) 0.34 (0.56) (2.49)
Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share) 0.33 (0.56) (1.54)
Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) 0 0 (0.95)
Diluted (in dollars per share) $ 0.33 $ (0.56) $ (2.49)